Literature DB >> 25294053

Progress of hearing loss in neurofibromatosis type 2: implications for future management.

Georgios Kontorinis1,2, Jaya Nichani3, Simon R Freeman3, Scott A Rutherford4, Samantha Mills5, Andrew T King4, Deborah Mawman3, Sue Huson6, Martin O'Driscoll3, D Gareth Evans6, Simon K W Lloyd3,7.   

Abstract

The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34% in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.

Entities:  

Keywords:  Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol

Mesh:

Year:  2014        PMID: 25294053     DOI: 10.1007/s00405-014-3317-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  37 in total

1.  Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2.

Authors:  M M Abaza; E Makariou; M Armstrong; A K Lalwani
Journal:  Laryngoscope       Date:  1996-06       Impact factor: 3.325

2.  Auditory brainstem implants in NF2 patients: results and review of the literature.

Authors:  Mario Sanna; Filippo Di Lella; Maurizio Guida; Paul Merkus
Journal:  Otol Neurotol       Date:  2012-02       Impact factor: 2.311

3.  Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes.

Authors:  Grant W Mallory; Bruce E Pollock; Robert L Foote; Matthew L Carlson; Colin L Driscoll; Michael J Link
Journal:  Neurosurgery       Date:  2014-03       Impact factor: 4.654

Review 4.  Neurofibromatosis type 2.

Authors:  Gareth R Evans; Simon K W Lloyd; Richard T Ramsden
Journal:  Adv Otorhinolaryngol       Date:  2011-02-24

5.  Cochlear implants to treat deafness caused by vestibular schwannomas.

Authors:  Payal Mukherjee; James D Ramsden; Nick Donnelly; Patrick Axon; Shakeel Saeed; Paul Fagan; Richard M Irving
Journal:  Otol Neurotol       Date:  2013-09       Impact factor: 2.311

6.  Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2.

Authors:  M Samii; C Matthies; M Tatagiba
Journal:  Neurosurgery       Date:  1997-04       Impact factor: 4.654

7.  Cochlear implantation in patients with vestibular schwannoma: a single United Kingdom center experience.

Authors:  Irumee Pai; Vikram Dhar; Catherine Kelleher; Terry Nunn; Steve Connor; Dan Jiang; Alec Fitzgerald O'Connor
Journal:  Laryngoscope       Date:  2013-04-24       Impact factor: 3.325

8.  A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; T Strachan; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

9.  Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results.

Authors:  Matthieu Peyre; Stéphane Goutagny; Alpha Bah; Daniele Bernardeschi; Béatrice Larroque; Olivier Sterkers; Michel Kalamarides
Journal:  Neurosurgery       Date:  2013-06       Impact factor: 4.654

10.  Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC.

Authors: 
Journal:  Otolaryngol Head Neck Surg       Date:  1995-09       Impact factor: 3.497

View more
  1 in total

1.  Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2022-01-18       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.